Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE  2 Randomized Clinical Trial

ConclusionsRisankizumab demonstrated durable efficacy and tolerability through 100  weeks; most patients who achieved ACR20 and MDA responses at week 52 maintained this achievement through week 100. There were no new safety signals in patients who had csDMARD-IR and bDMARD-IR.Trial RegistrationClinicalTrials.gov NCT03671148.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research